Meeting
2024 ASCO Annual Meeting
Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.
Authors
Joan Albanell
Hospital del Mar, CIBERONC-ISCIII; GEICAM Spanish Breast Cancer Group, Barcelona, Spain
Joan Albanell , Amy Williams , Maria Teresa Martínez , Hanna Ritzen , Lorena Paris , Miriam O'Connor , Luis De la Cruz Merino , Ana Santaballa , Noelia Martinez-Jañez , Fernando Moreno Antón , Isaura Fernández , Jesús Alarcón Company , Juan Antonio Guerra , Manuel Ruiz-Borrego , Patrick G. Morris , Marta Portela , Jesús Herranz , Rosalia Caballero , Mattias Bergqvist , Federico Gustavo Rojo Todo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT02690480
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 1028)
DOI
10.1200/JCO.2024.42.16_suppl.1028
Abstract #
1028
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).
First Author: Candace Bavette Mainor
Poster
2022 ASCO Annual Meeting
A novel analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and provides an option for efficacy assessments that could accelerate drug approvals.
First Author: Celine Yeh
Poster
2021 ASCO Annual Meeting
Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results.
First Author: Marina Maglakelidze
Poster
2024 ASCO Annual Meeting
Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study.
First Author: Sonia Pernas